Transdermal buprenorphine in chronic pain: indications and clinical experience

References

• Staats PS, Johnson RE. New perspectives on the pharmacology of opioids and their use in chronic pain. Prog. Anesthesiol.16, 235–249 (2002).
   Google Scholar
• Grossman SA, Benedetti C, Brock C et al. NCCN guidelines for cancer pain. NCCN Proceedings14, 135–150 (2000).
   Google Scholar
• Ferrell B, Casarett D, Epplin J et al. The management of persistent pain in older persons. J. Am. Geriatr. Soc.50(Suppl. 6), S205–S224 (2002).
   Google Scholar
• Masson AHB. Sublingual buprenorphine versus oral dihydrocodeine in postoperative pain. J. Int. Med. Res.9, 506–510 (1981).
   PubMed Web of Science ®Google Scholar
• Hanks GW. The clinical usefulness of agonist–antagonist opioid analgesics in chronic pain. Drug Alcohol Depend.20, 339–346 (1987).
   PubMed Web of Science ®Google Scholar
• Mercadante S. Transdermal buprenorphine in cancer pain: a renewed therapeutic opportunity. Support. Palliat. Cancer Care2, 117–122 (2006).
   Google Scholar
• Hans G. Buprenorphine – a review of its role in neuropathic pain. J. Opioid Manag.3, 195–206 (2007).
   PubMedGoogle Scholar
• Koppert W, Ihmsen H, Korber N et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain118, 15–22 (2005).
   PubMed Web of Science ®Google Scholar
• Sacerdote P. Opioids and the immune system. Palliat. Med.20(Suppl. 1), S9–S15 (2006).
   PubMed Web of Science ®Google Scholar
• Dagtekin O, Gerbershagen HJ, Wagner W, Petzke F, Radbruch L, Sabatowski R. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesth. Analg.105, 1442–1448 (2007).
   PubMed Web of Science ®Google Scholar
• Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int. J. Clin. Pract.133(Suppl.), 9–14 (2003).
   Google Scholar
• Grünenthal GmbH. Transtec Scientific Monograph (2002).
   Google Scholar
• Cowan A, Doxey JC, Harry EJR. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol.60, 547–554 (1977).
   PubMed Web of Science ®Google Scholar
• Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol.60, 537–545 (1977).
   PubMed Web of Science ®Google Scholar
• Evans HC, Easthope SE. Transdermal buprenorphine. Drugs63, 1999–2010 (2003).
   PubMed Web of Science ®Google Scholar
• Leander JD. Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and mice. Eur. J. Pharmacol.151, 457–461 (1988).
   PubMed Web of Science ®Google Scholar
• Martin WR, Eades CG, Thompson JA et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther.197, 517–532 (1976).
   PubMed Web of Science ®Google Scholar
• Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides21, 1141–1146 (2000).
   PubMedGoogle Scholar
• Dunn JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol.74, 627–633 (1981).
   PubMed Web of Science ®Google Scholar
• Tyers MB. A classification of opiate receptors that mediate antinociception in animals. Br. J. Pharmacol.69, 503–512 (1980).
   PubMed Web of Science ®Google Scholar
• Budd K. High-dose buprenorphine for postoperative analgesia. Anaesthesia36, 900–903 (1981).
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther.55, 569–580 (1994).
   PubMed Web of Science ®Google Scholar
• Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin. Pharmacokinet.37, 17–40 (1999).
   PubMed Web of Science ®Google Scholar
• Budd K. Buprenorphine: a review. Evidence Based Med. Prac.1–24 (2002).
   Google Scholar
• Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J. Pain Symptom Manage.29, 297–326 (2005).
   PubMed Web of Science ®Google Scholar
• Bohme K. Buprenorphine in a transdermal therapeutic system–a new option. Clin. Rheumatol.21(Suppl. 1), S13–S16 (2002).
   PubMed Web of Science ®Google Scholar
• Sittl R. Buprenorphine transdermal patch: clinical expert report. Grünenthal GmbH, Germany (2000).
   Google Scholar
• Rance MJ, Shillingford JS. The metabolism of phenolic opiates by rat intestine. Xenobiotica7, 529–536 (1997).
   Google Scholar
• Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci.60, 1953–1964 (1977).
   Google Scholar
• Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs17, 81–119 (1979).
   PubMed Web of Science ®Google Scholar
• Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br. J. Anaesth.64, 276–282 (1990).
   PubMed Web of Science ®Google Scholar
• Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur. J. Pain10, 743–748 (2006).
   PubMed Web of Science ®Google Scholar
• Moore RA, Sear JW, Baldwin D et al.Morphine kinetics before and after renal transplantation in man. Clin. Pharmacol. Ther.35, 641–645 (1997).
   Google Scholar
• Bohme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic15, 193–202 (2003).
   Google Scholar
• Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther.25, 150–168 (2003).
   PubMed Web of Science ®Google Scholar
• Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther.26, 1808–1820 (2004).
   PubMed Web of Science ®Google Scholar
• Radbruch L. Buprenorphine TDS: use in daily practice, benefits for patients. Int. J. Clin. Pract. Suppl.113, 19–22 (2003).
   Google Scholar
• Vielvoye-Kerkmeer APE. Long-term treatment with buprenorphine TDS in patients with chronic pain. Eur. J. Palliat. Care10(Suppl. 1), 17–19 (2003).
   Google Scholar
• Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support. Care Cancer15, 441–444 (2006).
   PubMedGoogle Scholar
• Poulain P, Denier W, Seremet M et al. Efficacy and safety of buprenorphine TDS 70 µg/h in patients with severe chronic cancer pain: a randomised multicentre, double-blind, placebo-controlled study. Eur. J. Pain10(Suppl. 1), S135 (2006) (Abstract 511)
   Google Scholar
• Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients. Curr. Med. Res. Opin21, 1147–1156 (2005).
   PubMed Web of Science ®Google Scholar
• Camba MA, The Opioid Study Group of the Spanish Pain Society. Transdermal buprenorphine for the management of nociceptive chronic pain. Rev. Soc. Esp. Dolor.11(Suppl. V), 22–30 (2004).
   Google Scholar
• Rodriguez-Lopez MJ, The Opioid Study Group of the Spanish Pain Society. Transdermal buprenorphine in the management of neuropathic pain. Rev. Soc. Esp. Dolor.11(Suppl. V), 11–21 (2004).
   Google Scholar
• Muriel C; The Opioid Study Group of the Spanish Pain Society. Assessment of buprenorphine transdermal patch in patients with cancer pain. Rev. Soc. Esp. Dolor.11(Suppl. V), 41–48 (2004).
   Google Scholar
• Barutell CDE, The Opioid Study Group of the Spanish Pain Society. Buprenorphine and tramadol. Rev. Soc. Esp. Dolor.11(Suppl. V), 31–40 (2004).
   Google Scholar
• Gonzalez-Escalada JR, The Opioid Study Group of the Spanish Pain Society. Use of buprenorphine and oral morphine in patients with chronic pain. Rev. Soc. Esp. Dolor.11(Suppl. V), 3–10 (2004).
   Google Scholar
• Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev. Neurotherapeutics5, 315–323 (2005).
   PubMedGoogle Scholar
• Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat. Med.20(Suppl. 1), S3–S8 (2006).
   PubMed Web of Science ®Google Scholar
• Kogel B, Christoph T, Strassburger W, Friderichs E. Interaction of µ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine on mice. Eur. J. Pain9, 599–611 (2005).
   PubMed Web of Science ®Google Scholar
• Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec®) in chronic pain patients. Pain Pract.7, 123–129 (2007).
   PubMedGoogle Scholar
• Mercadante S, Villari P, Ferrera P et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J. Pain Symptom Manage.32, 175–179 (2006).
   PubMedGoogle Scholar
• Ebner E, Wiedmann M. Transdermal buprenorphine in pregnancy. Schmerz20, 334–337 (2006).
   PubMedGoogle Scholar